Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004–2014

Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004–2014

Abstract Background This study analyzes the pattern of use of single agent anticancer therapy (SAACT) in the treatment and survival of advanced hepatocellular carcinoma (aHCC) before and after sorafenib was FDA approved in 2007. Methods Adult patients diagnosed with HCC and treated with only ACT fro...

Full description

Bibliographic Details
Main Authors: Aman Opneja, Gino Cioffi, Asrar Alahmadi, Nelroy Jones, Tin‐Yun Tang, Nirav Patil, David L. Bajor, Joel N. Saltzman, Amr Mohamed, Eva Selfridge, Ankit Mangla, Jill Barnholtz‐Sloan, Richard T. Lee
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Cancer Medicine
Subjects:
chemotherapy
facility type
hepatocellular carcinoma
income
insurance
survival
Online Access:https://doi.org/10.1002/cam4.3985

Internet

https://doi.org/10.1002/cam4.3985

Similar Items